Six months neoadjuvant imatinib improves resectability potential of gastric stromal tumors in Egyptian patients  by Saied, Gamal M. & Kensarah, Ahmed M.
lable at ScienceDirect
International Journal of Surgery 8 (2010) 105–108Contents lists avaiInternational Journal of Surgery
journal homepage: www.thei js .comSix months neoadjuvant imatinib improves resectability potential of gastric
stromal tumors in Egyptian patients
Gamal M. Saied a,*, Ahmed M. Kensarah b
aDepartment of General Surgery, Faculty of Medicine, Cairo University, Giza, Cairo 12311, Egypt
bDepartment of General Surgery, Faculty of Medicine, King Abdulaziz University, Kingdom of Saudi Arabiaa r t i c l e i n f o
Article history:
Received 31 July 2009
Received in revised form
23 September 2009
Accepted 28 September 2009
Available online 24 November 2009
Keywords:
Gastrointestinal stromal tumor
GISTs
Imatinib
Neoadjuvant therapy
Targeted therapy kit (Cd117)* Corresponding author. Tel.: þ20 37482262; fax: þ
E-mail address: gamal44@hotmail.com (G.M. Saied
1743-9191/$ – see front matter  2009 Surgical Asso
doi:10.1016/j.ijsu.2009.09.016a b s t r a c t
Objectives: Though recurrence is high, local excision is the preferred approach for dealing with gastric
stromal tumors. Achieving negative margins is mandatory, sometimes requiring subtotal gastrectomy.
Adjuvant imatinib is essential for advanced cases and prolonging survival; however, there is not enough
data to recommend its use before surgery to increase resectability. The current study aims at investi-
gating this concept in Egyptian patients.
Patients and methods: The study included 16 patients (13 males, 3 females, mean age 60 years) presenting
with gastrointestinal stromal tumors (GISTs) who were candidates for emergency (n ¼ 3) or elective
(n ¼ 13) surgery. Investigations included endoscopy (þbiopsy), sonography, and computed tomography
(CT). Patients were enrolled in two groups: A (n ¼ 6: projected to planned surgery) and B (n ¼ 7:
harboring c-kit þve tumors). Each B patient received imatinib (400 mg/day) for 6 months before surgery.
Clinical and radiological evaluation was at day 100. The Chi-square test was used to check size changes,
and p at <0.02535 was considered signiﬁcant.
Results: All patients had abdominal discomfort, while 62.5% had epigastric pain, and 12.5% had hema-
temesis. Tumor sizes ranged from 8.4 to 20 cm 2/3 were located in the upper stomach. Five patients
(31.3%) harbored lesions with low risk malignancy, eight (50%) with moderate risk and three (18.8%) with
high risk. Wedge gastrectomy was the most common operation performed (81.25%) while partial
gastrectomy was carried out in the rest, reporting no recurrence for 6 months. Not determined in group A
patients, c-kit status was strongly positive in all members of group B; in two of them treatment was
suspended due to poor response.
Conclusion: Imatinib has an acceptable safety proﬁle and can be considered as a neoadjuvant therapy in
GISTs. Until clear guidelines have been developed, we report that a 6 month intake may noticeably
increase their resectability potential and improve prognosis.
 2009 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Gastrointestinal stromal tumors (GISTs) were not recognized as
a distinct entity until their origin from the interstitial cells of Cajal –
or their predecessors – was established. These turn into epithelioid,
undifferentiated cells branded by over expression of the tyrosine
kinase receptor KIT (CD117)1,2 GISTs span a wide clinical spectrum
from benign to highly malignant or even metastatic,3 and harbor
the potential risk of local and distant recurrence making them
difﬁcult to cure.4,5 The only treatment for metastatic disease is
surgery, while chemotherapy and radiation treatments have proven
ineffective.4 While the minority of GISTs affect the small intestine,20 33356251.
).
ciates Ltd. Published by Elsevier Ltcolon, rectum and mesentery, studies also demonstrate their
prevalence in the stomach (60%), particularly in elderly males,
reaching a zenith at age 60 years,6–8 though occasionally also
affecting children. Requiring immediate surgery, bleeding is the
most common presentation of gastric stromal tumors (50%) and is
usually associated with ulceration in the lumen.9 Other patients
present with abdominal pain, palpablemass, obstructive symptoms
or minor bleeding episodes.6 Endoscopy can possibly disclose the
gastric tumor as a submucosal mass, and computed tomography
(CT) [or magnetic resonance imaging (MRI)] scans may give diag-
nostic suggestions, but a ﬁrm diagnosis is only certain after path-
ologic study of the biopsy or resected specimens. Being sensitive,
rapid and reliable,10 it is preferable to keep CT scans to measure
response to adjuvant therapy if used after surgery. It is difﬁcult for
surgeons to select the most suitable procedure to pursue, and as
late as 2001 local resection was considered adequate.11 The rapidd. All rights reserved.
Table 1
Group B (n¼ 7) Reason for giving neoadjuvant imatinib followed by delayed surgery.
Sn Reason Notes
1 Vague but strongly symptomatic local recurrence after previous
wedge resection.
a b
2 Noncomplicated large antral lesion (>12 cm). b
3 Radiologically resectable lesion but with solitary
left lobe secondary.
b
4 Greater curvature mass very close to the splenic hilum
and pancreatic tail.
Resection without splenectomy was thought impossible.
b
5 Localized large sized mass recurrent after previous wedge
gastrectomy (distal stomach) with extragastric lymph
node metastasis.
a
6 Large tumor at greater curvature very close to body of pancreas
and acquiring accessory blood supply from there.
b
7 Greater curvature large mass. Heavy adhesion to the
greater omentum in CT.
b
a Patient did not receive imatinib following previous surgery.
b Considered temporarily irresectable due to local reasons. Large size is the cause
in cases 2, 5 and 6.
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exerted by the primary tumor on its remote metastases via circu-
lating angiostatin.12,13 Currently, achieving negative surgical
margins on frozen section examination is mandatory14 and this
entails segmental resection, at times amounting to subtotal
gastrectomy and omentectomy as in perforation, bleeding or when
a tumor ruptures.9,15 Being of no proﬁtable use lymphadenectomy
is not required and adjuvant therapy with the KIT tyrosine kinase
inhibitor imatinib remains essential for high risk or metastasizing
tumors, as it signiﬁcantly prolongs survival.16,17 Recently, much
attention has been focused on using this drug as a neoadjuvant
therapy,18 but earlier reports included diminutive formal analyses
of data concerning success rates that might have been caused by
this approach. Notwithstanding this, and being impressed by the
amazing pathological response it induces, particularly on tumor
volume,19 the need to launch this new discipline on Egyptian
patients was recognized.
2. Patients and methods
This prospective study was completed at Cairo University
hospitals and also in private practice, from May 2007 through to
January 2009. It included 16 patients (13 males, 3 females, agesSize before and After
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Fig. 1. Analysis of sranging from 38 to 72 years (mean ¼ 60)) presenting with sus-
pected gastric stromal tumors and who were candidates for
emergency (n ¼ 3) or elective (n ¼ 13) surgery. Investigations
included endoscopy, endosonography and endoscopic biopsy,
while extra luminal spread and lymph node status were assessed
by CT; however, one patient required percutaneous drainage of
abdominal sepsis as a preliminary step. Meticulous analyses of
patients’ symptoms were enough in all cases to suggest that GIST
was likely and investigations were needed only to conﬁrm diag-
nosis and to assess operability. In six of those patients, tumors were
immediately amenable to planned surgical resection and were
sequestrated as group A, while the remaining seven patients – all
harboring tumors with c-kit þve biopsy specimens – were enrolled
as group B. Though all lesions in group B patients were localized in
CT, it was unwise from the surgeon’s perspective to proceed
immediately due to different reasons (Table 1). To improve
compliance, it was important to clarify to each individual patient
what GIST is, and to assure him that his illness may be controllable,
and to provide him with full information about the treatment
protocol, and to have his signed consent. Each group B patient
received imatinib (400 mg/day orally) for 6 months before surgery.
Clinical and radiological evaluation of drug effect was at day 100,
and the Chi-square test was used to check the signiﬁcance of size
reduction induced by treatment. A value of p < 0.02535 was
considered signiﬁcant. Two patients had a poor response to the
drug and were shifted to classical management as in group A.
Imatinib–associated side effects were not identiﬁed in this series.3. Results
Clinically, all patients presented with abdominal discomfort,
while only 10 of them (62.5%%) had epigastric pain, and two (12.5%)
had hematemesis. Mean tumor size was 13.2 cm (8.4–20), mostly
located in the upper stomach (68.8%). Five patients (31.3%)
harbored lesions with low risk malignancy, eight with moderate
(50%) and three (18.8%) with high risk. While strongly positive in
the seven patients who received neoadjuvant imatinib, the c-kit
status was not determined in patients of group A. Preoperative
imatinib for 6 months succeeded in inducing spectacular symp-
tomatic improvement in ﬁve patients with an overall reduction in
tumor size of 29%, as seen via CT (Fig. 1), with a concomitant
reduction in tumor density, which subsequently made resectionBox & Whisker Plot
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Table 2
Group B (n¼7) Patient/tumor characteristics and management and results.
SNa Age
(years)
Locationf &
size (cm)
Indication for
neo-imatinib
Residual size
(RS) in cm
(RS) % of
initiale
Response rate Postoperative histpathology Post-ttt
op.procedure
1 61 D/12 Unresectableb 8.8 73.30 26.7 Hypocellularity þ necrosis WG
2 55 P/12 Unresectable 12d – – –
3 59 P/8.4 Unresectable 7.6 90.5 9.5c Hypocellularity þ necrosisþcysts WG
4 63 P/11.2 Unresectable 7.6 67.90 32.1 Hypocellularity þ necrosis WG
5 58 P/17.6 Large size 11.2 64.20 35.8 Hypocellularity þ necrosis PG
6 60 P/20 Large size 12.0 60.00 40.0 Necrosis PG
7 48 P/11.2 Unresectable 11.2d – – –
a All are males with histologically proven c-kit þ ve gastric stromal tumors.
b Unresectability determined preoperatively by CT or MRI.
c Poor response.
d No response – treatment suspended.
e Average residual size % of the initial ¼ 71.18%.
f Location in stomach in D : distal – P: proximal (%) Reduction in size ¼ Mean Response rate: 28.82% Type of gastrectomy: WG: Wedge PG: Partial.
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resection. Having no operative mortality, wedge gastrectomy was
the most common procedure (81.25%) while partial gastrectomy
was performed in three patients (Table 2). Within the following 6
months there was no evidence of recurrence. In two patients the
response to the drug was poor and treatment was suspended.4. Discussion
Currently, most clinicians working on GISTs recommend
attempting complete or near complete surgical resection of gastric
lesions. Low grade tumors have excellent prognosis and resection
may be curative, while recurrence is the rule in high grade ones. For
the latter, post operative imatinib is suggested even if resection is
incomplete,17 as this is associated with a survival beneﬁt when
compared to imatinib18 or surgery alone. This must be followed by
strict follow-up even if the response is outstanding, repeating
surgery if recurrence occurs. Only a little is known about using this
drug prior to surgery19,20 and the aim of this present trial was to
study this modality in Egyptian patients. In our minds it was clear
that gastric lesions, in particular, reveal themselves by their large
sizes and that resection may be difﬁcult or incomplete, particularly
when extragastric lymph node metastasis is present and/or the
tumor is ﬁxed to adjacent organs, as in case numbers 4, 6 and7of the
present series. This creates an ideal situation for making use of
preoperative imatinib to increase resectability potential. Likewise,
a comprehensible study performed by Florien in 2007 demon-
strated appreciable reduction of tumor diameter in a linear fashion
following preoperative imatinib therapy, monitoring at the same
time a concomitant exponential reduction in volume; the latter
being more sensitive for disclosing tumor response than diameter
measurement.21–23 Hohenberger et al. recently reported 18 patients
manipulated in this way and concluded that even a partial response
reﬂects a better outcome than in progressive disease.24 In the
present study, the efﬁcacy of imatinib on the tumor size was
adequately disclosed on CT, showing a 29% reduction -with or
without cystic changes- and histological examination detected
residual (or no) tumor cells, scant vascularity and scattered
inﬂammatory cells. Reduction in tumor size was accompanied by
reduction in tumor density observed in the preoperative CT and the
local causes in cases 4, 6 and 7 were less evident. These results are
strikingly similar to the results reported byAndtbacka et al.25 2 years
ago who also advised performing surgery as early as possible after
imatinib therapy as complete resection is rarely achieved once
tumor progression re-occurs. The c-kit immunohistochemistry in
tumor cells in the seven patients receiving pre-treatment was
stronglypositive (fourwerehighlymalignant),while in twopatients
poor response dictated treatment suspension. In no case was theremission complete; the same was also observed by Langer et al. in
2003.26 Due to this achievement, we advocate regularly following
the neoadjuvant policy in dealing with GISTs, but a universal deci-
sion to switch to this new regimen needs further studies. In fact, we
share Raut27 and his viewpoint that it is too early to do so now, and
even to adequately determine the dose of the drug, optimal duration
of treatment and to select the best time of surgical intervention.We
propose the latter to be immediately after maximal drug effect but
before possible disease progression caused by secondary muta-
tions.28 However, until more dose-response studies become avail-
able, surgeons who want to adopt this regimen should use the
lowest effective dose for the shortest possible duration; 400 mg
daily for 6 months is most likely the optimum. Escalation or
doubling the dose has no effect as tolerance is not known. Should no
evidence of response appear clinically or in the CT in the ﬁrstmonth,
then treatment must be stopped, and resection arranged for.
Moreover, it is reasonable tonotify patients receiving the drug about
probable side effects and one should be aware about the disadvan-
tage of using thedrug in type2diabetics receiving insulin,29 and also
in patientswith splenomegaly.30 The real concernwith this regimen
is the possibility of developing resistance to imatinib which is
ascribed to secondary mutations, as happens in myeloid leukemia;
this is an expected concern in metastasizing cases intended to
receive post operative therapy. Testing for this mutation in resected
material31,32 is a missing item from this work.5. Conclusion
In the wake of the recent thesis on this neoadjuvant approach
for malignancy, it might be relevant to start thinking of making use
of such a function as the imatinib treatment of gastric stromal
tumors. Our ﬁndings at this juncture are encouraging despite the
small number of patients, absence of a control group and also in the
face of observably deﬁcient earlier clinical trials. Until clear
guidelines are developed, a daily dose of 400 mg before surgery
may be valid for increasing resectability potential. A 6 month
treatment succeeded in reducing tumor size by 29%, but individual
dose titration is not recommended. Also, an absent early response
means prompt switching to surgery.
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